Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Drugs in R&D
Published in: Drugs in R&D 1/2015

Open Access 01-03-2015 | Original Research Article

Budget Impact Analysis of Warfarin Reversal Therapies Among Hip Fracture Patients in Finland

Authors: Timo Purmonen, Soili Törmälehto, Niina Säävuori, Hannu Kokki

Published in: Drugs in R&D | Issue 1/2015

Login to get access

Abstract

Background

Hip fractures require operation within 36–48 h, and they are most common in the elderly. A high International Normalized Ratio should be corrected before surgery. In the current study, we analyzed the budget impact of various warfarin reversal approaches.

Methods

Four reversal strategies were chosen for the budget impact analysis: the temporary withholding of warfarin, administration of vitamin K, fresh frozen plasma (FFP), and a four-factor prothrombin complex concentrate (PCC).

Results

We estimated that, annually, 410 hip fracture patients potentially require warfarin reversal in Finland. The least costly treatment was vitamin K, which accounted for €289,000 in direct healthcare costs, and the most costly treatment option was warfarin cessation, which accounted for €1,157,000. In the budget impact analysis, vitamin K, PCC and FFP would be cost-saving to healthcare compared with the current treatment mix.

Conclusion

The various warfarin reversal strategies have different onset times, which may substantially impact the subsequent healthcare costs.
Literature
1.
2.
de Laet CE, van Hout BA, Burger H, Hofman A, Pols HA. Bone density and risk of hip fracture in men and women: cross sectional analysis. BMJ. 1997;26:221–5.CrossRef
3.
Korhonen N, Niemi S, Parkkari J, Sievänen H, Palvanen M, Kannus P. Continuous decline in incidence of hip fracture: nationwide statistics from Finland between 1970 and 2010. Osteoporos Int. 2013;24:1599–603.CrossRefPubMed
4.
Shiga T, Wajima Z, Ohe Y. Is operative delay associated with increased mortality of hip fracture patients? Systematic review meta-analysis and meta-regression. Can J Anesth. 2008;55:135–9.CrossRef
5.
National Clinical Guideline Centre. The management of hip fracture in adults. London: National Clinical Guideline Centre; 2011. www.​ncgc.​ac.​uk. Accessed 21 Mar 2014.
6.
Virjo I, Mäkelä K, Aho J, Kalliola P, Kurunmäki H, Uusitalo L, Valli M, Ylinen S. Who receives anticoagulant treatment with warfarin and why? A population-based study in Finland. Scand J Prim Health Care. 2010;28:237–41.CrossRefPubMedCentralPubMed
7.
Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G, American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e44S–88S.PubMedCentralPubMed
8.
Ageno W, Garcia D, Aguilar MI, Douketis J, Finazzi G, Imberti D, Iorio A, Key NS, Lim W, Marietta M, Prisco D, Sarode R, Testa S, Tosetto A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. Am J Hematol. 2009;84:584–8.CrossRefPubMed
9.
Burbury KL, Milner A, Snooks B, Jupe D, Westerman DA. Short-term warfarin reversal for elective surgery–using low-dose intravenous vitamin K: safe, reliable and convenient*. Br J Haematol. 2011;154:626–34.CrossRefPubMed
10.
Hujanen T, Kapiainen S, Tuominen U, Pekurinen M. Terveydenhuollon yksikkökustannukset Suomessa vuonna 2006. (Health care unit cost in Finland in 2006). Report of National Institute for Health and Welfare, Helsinki, Finland 2008. http://​www.​julkari.​fi/​handle/​10024/​76754. Accessed 21 Mar 2014.
11.
12.
Kapiainen S, Väisänen A, Haula T. Terveyden- ja sosiaalihuollon yksikkökustannukset Suomessa vuonna 2011. (Social- and health care unit costs in Finland in 2011). Report of National Institute for Health and Welfare, Helsinki, 2014. http://​www.​julkari.​fi/​handle/​10024/​114683. Accessed 21 Mar 2014.
13.
Siegmeth AW, Gurusamy K, Parker MJ. Delay to surgery prolongs hospital stay in patients with fractures of the proximal femur. J Bone Jt Surg Br. 2005;87:1123–6.CrossRef
14.
Weller I, Wai EK, Jaglal S, Kreder HJ. The effect of hospital type and surgical delay on mortality after surgery for hip fracture. J Bone Jt Surg Br. 2005;87:361–6.CrossRef
15.
Bergeron E, Lavoie A, Moore L, Bamvita JM, Ratte S, Gravel C, Clas D. Is the delay to surgery for isolated hip fracture predictive of outcome in efficient systems? J Trauma. 2006;60:753–7.CrossRefPubMed
16.
Dentali F, Ageno W, Crowther M. Treatment of coumarin-associated coagulopathy: a systematic review and proposed treatment algorithms. J Thromb Haemost. 2006;4:1853–63.CrossRefPubMed
17.
Leonidou A, Rallan R, Cox N, Pagkalos J, Luscombe J. Comparison of different warfarin reversal protocols on surgical delay and complication rate in hip fracture patients. J Orthop Surg (Hong Kong). 2013;21:142–5.
18.
Woods K, Douketis JD, Kathirgamanathan K, Yi Q, Crowther MA. Low-dose oral vitamin K to normalize the international normalized ratio prior to surgery in patients who require temporary interruption of warfarin. J Thromb Thrombolysis. 2007;24:93–7.CrossRefPubMed
19.
Steib A, Barre J, Mertes M, Mertes M, Morel MH, Nathan N, Ozier Y, Treger M, Samama CM. Can oral vitamin K before elective surgery substitute for preoperative heparin bridging in patients on vitamin K antagonists? J Thromb Haemost. 2010;8:499–503.CrossRefPubMed
20.
Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol. 1999;83(286–8):A6–7.
21.
Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med. 1999;159:2721–4.CrossRefPubMed
22.
Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163:2469–73.CrossRefPubMed
23.
Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol. 2006;126:133–9.CrossRefPubMed
24.
Schick KS, Fertmann JM, Jauch KW, Hoffmann JN. Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care. 2009;13:R191.CrossRefPubMedCentralPubMed
25.
Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang. 2010;99:251–60.CrossRefPubMed
26.
27.
Bruce D, Nokes TJ. Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital. Crit Care. 2008;12:R105.CrossRefPubMedCentralPubMed
28.
Theusinger OM, Baulig W, Seifert B, Emmert MY, Spahn DR, Asmis LM. Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. Br J Anaesth. 2011;106:505–11.CrossRefPubMed
29.
van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, Ploeger B, Strengers PF. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313–20.CrossRefPubMed
30.
31.
32.
Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34:2094–106.CrossRefPubMed
Metadata
Title
Budget Impact Analysis of Warfarin Reversal Therapies Among Hip Fracture Patients in Finland
Authors
Timo Purmonen
Soili Törmälehto
Niina Säävuori
Hannu Kokki
Publication date
01-03-2015
Publisher
Springer International Publishing
Published in
Drugs in R&D / Issue 1/2015
Print ISSN: 1174-5886
Electronic ISSN: 1179-6901
DOI
https://doi.org/10.1007/s40268-015-0088-6

Other articles of this Issue 1/2015

Drugs in R&D 1/2015 Go to the issue

Original Research Article

Pharmacokinetics of Cefozopran by Single and Multiple Intravenous Infusions in Healthy Chinese Volunteers

Current Opinion

Pharmaceutical, Biological, and Clinical Properties of Botulinum Neurotoxin Type A Products

Original Research Article

Saliva Versus Plasma Bioequivalence of Rusovastatin in Humans: Validation of Class III Drugs of the Salivary Excretion Classification System

Commentary

‘Similar To’ Is Not ‘Identical With’, and ‘Identical With’ Is Not ‘The Same As’

Review Article

mTOR: A Potential Therapeutic Target in Osteoarthritis?

Leading Article

Auranofin: Repurposing an Old Drug for a Golden New Age